Intellia’s One-Time CRISPR Therapy Cuts Angioedema Attacks 87% in Phase 3 Trial
Intellia’s one-time CRISPR therapy lonvo-z met its primary endpoint in the Phase 3 HAELO trial, cutting hereditary angioedema attacks by 87% versus placebo — a still-investigational result now heading into FDA review.







